{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-21-005807","form_type":"8-K","ticker":"UG","cik":"0000101295","company_name":"UNITED GUARDIAN INC","filed_at":"2021-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.855132+00:00","generated_at":"2026-06-29T14:29:25.030919+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"United-Guardian Q2 sales up 24% YoY; EPS $0.29 vs $0.26","bullets":["Q2 2021 revenue $3.66M, up 24% from $2.95M in Q2 2020; net income $1.34M ($0.29 per share) vs. $1.19M ($0.26).","H1 2021 revenue $7.09M (+13% YoY); net income $2.53M ($0.55 per share) vs. $1.98M ($0.43).","Cosmetic ingredient sales surged 68% YoY in Q2; pharmaceutical sales strong despite ending Medicaid participation.","President cautions Delta variant may impact cosmetic ingredient sales in H2 but expects pharmaceutical resilience."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-21-005807","json":"https://secwatch.observer/filing/0001171843-21-005807.json","markdown":"https://secwatch.observer/filing/0001171843-21-005807.md","text":"https://secwatch.observer/filing/0001171843-21-005807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/101295/000117184321005807/0001171843-21-005807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/101295/000117184321005807/f8k_080921.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T14:29:25.030919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}